NASDAQ · AVTX
Avalo Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AVTX: Nov 5, 2026
Avalo Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.63. The reported EPS for the same quarter last year was $-2.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.63 | $-0.45 | $-0.86 | 5 |
| Dec 2026 | $-0.65 | $-0.43 | $-0.89 | 4 |
| Mar 2027 | $-0.68 | $-0.49 | $-0.96 | 3 |
| Jun 2027 | $-0.74 | $-0.55 | $-1.08 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Fintel · Zacks- BNK Invest · Sep 25, 3:19 PM EDTNoteworthy Friday Option Activity: OFG, AVTX, VSTAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OFG Bancorp (Symbol: OFG), where a total of 2,642 contracts have traded so far, representing approximately 264,200 underlying shares. That amounts to about 95.5% of OFG'
- RTTNews · Jun 24, 4:40 AM EDTAvalo Appoints Ron Philips To Its Board Of Directors; Abdakibart Phase 3 Set For H1 2027(RTTNews) – Avalo Therapeutics, Inc. (AVTX), a clinical-stage biotechnology company, announced the appointment of Ron Philips to its Board of Directors.
- Fintel · May 14, 8:14 AM EDTAvalo Therapeutics (AVTX) Price Target Increased by 18.49% to 47.94The average one-year price target for Avalo Therapeutics (NasdaqCM:AVTX) has been revised to $47.94 / share. This is an increase of 18.49% from the prior estimate of $40.46 dated April 25, 2026. The price target is an average of many targets provided by analys
- RTTNews · May 6, 4:16 AM EDTAvalo Prices $375M Offering Following Strong Phase 2 Abdakibart Data; Stock Up(RTTNews) – Avalo Therapeutics, Inc. (AVTX) has priced a $375 million public offering, a financing that positions the company as it advances multiple clinical and preclinical assets across immunology and inflammatory diseases.
- Fintel · Apr 9, 8:03 PM EDTWolfe Research Initiates Coverage of Avalo Therapeutics (AVTX) with Outperform RecommendationFintel reports that on April 9, 2026, Wolfe Research initiated coverage of Avalo Therapeutics (NasdaqCM:AVTX) with a Outperform recommendation. Analyst Price Forecast Suggests 184.13% Upside
- Fintel · Apr 6, 8:04 PM EDTCitizens Initiates Coverage of Avalo Therapeutics (AVTX) with Market Outperform RecommendationFintel reports that on April 6, 2026, Citizens initiated coverage of Avalo Therapeutics (NasdaqCM:AVTX) with a Market Outperform recommendation. Analyst Price Forecast Suggests 108.03% Upside
- Zacks · Apr 6, 11:10 AM EDTZacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo TherapeuticsSmall drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
- Zacks · Apr 3, 9:55 AM EDTWall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Apr 2, 10:00 AM EDT5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthInnovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
- Zacks · Mar 26, 11:53 AM EDTCORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian CancerCorcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.
- Fintel · Feb 2, 2:13 PM ESTGuggenheim Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationFintel reports that on February 2, 2026, Guggenheim initiated coverage of Avalo Therapeutics (NasdaqCM:AVTX) with a Buy recommendation. Analyst Price Forecast Suggests 132.05% Upside
- Fintel · Dec 18, 7:03 AM ESTMizuho Initiates Coverage of Avalo Therapeutics (AVTX) with Outperform RecommendationFintel reports that on December 18, 2025, Mizuho initiated coverage of Avalo Therapeutics (NasdaqCM:AVTX) with a Outperform recommendation. Analyst Price Forecast Suggests 78.64% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Avalo Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.